Medical uses:

Imjudo is a CTLA-4 blocking antibody used in combination with Imfinzi (durvalumab) for the treatment of adults with:

1. Unresectable hepatocellular carcinoma (uHCC): This means the cancer cannot be removed by surgery.
2. Metastatic non-small cell lung cancer (NSCLC): Specifically for patients without sensitizing EGFR mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and in combination with platinum-based chemotherapy.

Recommended Dosage:

• Administration: Imjudo is administered as a single infusion (drip) into a vein, lasting about 60 minutes. The first dose of Imfinzi (durvalumab) is given on the same day as Imjudo. Subsequent doses of Imfinzi are given every 28 days.

For uHCC:

• Patients weighing 30 kg or more: The recommended dose of Imjudo is 300 mg, given as a single dose along with Imfinzi (durvalumab) 1,500 mg on Day 1 of Cycle 1. Imfinzi is then continued as a single agent every 28 days.
• Patients weighing less than 30 kg: The recommended dose of Imjudo is 4 mg/kg, given as a single dose along with Imfinzi (durvalumab) 20 mg/kg on Day 1 of Cycle 1. Imfinzi is then continued as a single agent every 28 days.

For Metastatic NSCLC:

• Patients weighing 30 kg or more: The recommended dose of Imjudo is 75 mg every 21 days, in combination with Imfinzi (durvalumab) 1,500 mg and platinum-based chemotherapy for 4 cycles. Afterward, Imfinzi 1,500 mg is administered every 28 days as a single agent, along with histology-based pemetrexed therapy every 28 days. A fifth dose of Imjudo 75 mg is given with the sixth dose of Imfinzi at week 16.
• Patients weighing less than 30 kg: The recommended dose is 1 mg/kg every 21 days, in combination with Imfinzi (durvalumab) 20 mg/kg and platinum-based chemotherapy for 4 cycles. Afterward, Imfinzi 20 mg/kg is administered every 28 days as a single agent, along with histology-based pemetrexed therapy every 28 days. A fifth dose of Imjudo 1 mg/kg is given with the sixth dose of Imfinzi at week 16.

Warnings & Precautions:

Imjudo 25 mg/1.25 mL, when used with Imfinzi (durvalumab), can lead to immune-mediated hypophysitis, which may cause hypopituitarism. Symptomatic treatment, including hormone replacement, should be initiated as needed.

Patients should be monitored for hyperglycemia or other signs of diabetes, and insulin therapy should be started if necessary. Depending on the severity, treatment with Imjudo and durvalumab may need to be withheld or permanently discontinued.

Imjudo in combination with Imfinzi can also cause immune-mediated rash or dermatitis. Mild to moderate non-exfoliative rashes may be treated with topical corticosteroids or emollients.

Imjudo 300 mg/15 mL, when administered with Imfinzi, can result in severe or life-threatening infusion-related reactions. Patients should be assessed for these reactions, and treatment should be interrupted, slowed, or permanently stopped based on the severity.

Imjudo can cause fetal harm if given to a pregnant woman. Women of reproductive age should use effective contraception during treatment with Imjudo and for 90 days after the last dose.

Documentation & Availability :

Documents  required to import IMJUDO  to India? 

IMJUDO (tremelimumab-actl) injections can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:

1. 2 ID proofs along with PAN card details along with attested scanned copies
2. Valid doctor prescription scanned copy
3. Doctor’s MCI number
4. Doctor’s mobile number
5. Patients diagnostic reports

How is the order confirmed? 

The order will be confirmed only after the receipt of:

1. The above-mentioned documents and drug availability.
2. Import permit if applicable.

Sourcing & Delivery:

The Rx4U team has extensive experience in sourcing  IMJUDO (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.

 FAQ:

What is the Generic Name for Imjudo®?

The generic name for Imjudo® is Tremelimumab.

Who manufactures Imjudo®?

Imjudo® is manufactured by AstraZeneca Pharmaceuticals LP.

Is Imjudo® FDA approved?

Yes, Imjudo® was approved by the FDA on October 21, 2022.

Where can I find the best price for Imjudo® in India?

For the best price on Imjudo in India, contact the Rx4u team.

What are the available dosages and forms of Imjudo®?

Imjudo® is available as an injection in two forms: 300 mg/15 mL (20 mg/mL) and 25 mg/1.25 mL (20 mg/mL) solution in single-dose vials for intravenous administration.

What are the common side effects of Imjudo®?

For patients with uHCC, common side effects include diarrhea, rash, fatigue, abdominal pain, pruritus, and musculoskeletal pain. For patients with metastatic NSCLC, common side effects include fatigue, nausea, rash, musculoskeletal pain, decreased appetite, and diarrhea.

How much does Imjudo cost in India?

The price of Imjudo in India can vary due to international factors. To purchase this medication legally, you can reach out to Rx4u team.

What are the storage conditions for Imjudo®?

Store Imjudo® in a refrigerator at 2 to 8°C (36 to 46°F) in its original carton to protect it from light. Do not freeze or shake it.

Is it safe to buy Imjudo® online in India?

Yes, you can safely purchase Imjudo® online in India through https://rx4u.in/.

*Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.